Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalifrelimab + Pembrolizumab in Advanced NSCLC
NCT03411473Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of zalifrelimab in non-small cell lung cancer (NSCLC), sponsored by Agenus Inc.. Started Oct 2017; status: terminated.
02
Drugs
zalifrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03411473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03411473.